Novo Nordisk’s quarterly beat and steerage improve did little to resolve Wall Road’s greatest concern: whether or not the Ozempic maker has a convincing path again to sustainable development as competitors from Eli Lilly intensifies.
Analysts stated the better-than-expected quarter benefited from rebate changes and different short-term elements, weight problems drug gross sales have been broadly according to expectations, and oral Wegovy barely missed forecasts.
On the similar time, Novo reported one other blended medical end result for next-generation weight-loss drug CagriSema, reinforcing investor questions in regards to the firm’s longer-term pipeline.
“General nothing to encourage,” Citi analysts wrote, whereas Jefferies stated the steerage improve left little room for consensus gross sales estimates to maneuver increased.
The Danish drugmaker hiked its full-year steerage and stated it now expects adjusted gross sales and working revenue to be down 6% to flat at fixed trade charges, an enchancment from earlier steerage of a decline of between 4% and 12% for each metrics.
Eli Lilly shares have outperformed Novo ADRs over the previous 12 months.
Novo is racing to revive investor confidence in its pipeline and skill to execute, particularly within the difficult U.S. market, amid intense strain from Eli Lilly’s rival medicines Zepbound and Mounjaro, which have quickly gained market share regardless of being launched years after Novo’s.
Coming into Wednesday buying and selling, the corporate’s Danish shares had fallen about 5% year-to-date and have been down almost 70% from their mid-2024 peak, even when they’ve recovered some floor this 12 months following the profitable launch of the Wegovy capsule.
Novo stated the improved outlook was pushed by elevated expectations for GLP-1 product gross sales.
“The Wegovy product portfolio stays a key development driver for Novo Nordisk in 2026, led by the continued fast adoption of Wegovy capsule within the US, which has reached greater than 5 million prescriptions since its launch, alongside encouraging early uptake in markets outdoors the US and the rollout of Wegovy [high dose],” stated CEO Mike Doustdar in an announcement.
Novo’s American depositary receipts fell 6% in after-hours buying and selling Tuesday after the quarterly report was printed at some point sooner than anticipated.
